share_log

VIVXF: OxC-beta Approved in Vietnam…

VIVXF: OxC-beta Approved in Vietnam…

VIVXF:越南批准OXC-BETA…
Benzinga Real-time News ·  2022/05/09 10:16
By David Bautz, PhD
作者:David Bautz博士
OTC:VIVXF
场外交易:VIVXF
READ THE FULL VIVXF RESEARCH REPORT
阅读完整的VIVXF研究报告
Business Update
商业动态
OxC-beta Approved in Vietnam; Looking for Sales Ramp in 2H22
OXC-Beta在越南获批;寻求在2小时22秒内实现销售增长
Avivagen, Inc. (OTC:VIVXF) is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promote the growth and overall health of the animal through support of the host's innate immune system. Avivagen discovered that β-carotene polymerizes with oxygen into a unique class of compounds (oxidized β-carotene, OxBC) that promote immunological health and are the basis of Avivagen's OxC-beta™ technology. Numerous studies conducted by Avivagen and...
Avivagen,Inc.(场外交易代码:VIVXF)正在开发支持动物健康的产品,其中包括用专有化合物取代牲畜饲料中的抗生素,这些化合物通过支持宿主的先...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发